ACAD: ACADIA Pharmaceuticals Inc. Total Debt to Capital

Public company logo of ACADIA Pharmaceuticals Inc. (ACAD)

The financial quote visualization for ACADIA Pharmaceuticals (ACAD) on the GURU.Markets platform demonstrates a total debt-to-equity ratio of 0.06. ACADIA Pharmaceuticals (ACAD) is mitigating risks through partnerships with neurobiological centers to expedite therapy launches. The brand's high authority in treating CNS disorders ensures physician loyalty. Stable drug sales and internal development cycles render the business profitability independent of external economic fluctuations.

ACAD - ACADIA Pharmaceuticals Inc. Total Debt to Capital over the range 07/04/2022 - 10/29/2026

Metric breakdowns and analytics for ACADIA Corp (ACAD)

- price and consensus price forecast:
Price Chart ACADIA Pharmaceuticals Inc.|ACAD - Broker Consensus Forecast
- market capitalization information:
Market Capitalization ACADIA Pharmaceuticals|ACAD - Total Enterprise Value
- book capitalization indicators:
Accounting Value per Share ACADIA Pharmaceuticals|ACAD - Book Capitalization|Market Value to Book Value Ratio acadia-pharm.com|ACAD - Aggregate Asset Value
- issuer credit burden and liquidity indicators:
Debt to Equity ACADIA Pharmaceuticals|ACAD - Long-Term Liabilities to Capital|Short-Term Debt to Capital ACADIA Pharmaceuticals|ACAD - Company Aggregate Debts|Debts to Book Capitalization ACADIA Pharmaceuticals|ACAD - Company Long-Term Liabilities|Company Short-Term Debts ACADIA Pharmaceuticals
Basic company analysis:ACADIA Pharmaceuticals Inc., ACAD
Core merchandise of ACADIA Corp

Fundamental issuer selection requires a rigorous analysis of debt load to eliminate default risk during market volatility. This ratio measures the proportion of borrowed funds relative to equity, allowing for an assessment of the financial stability of ACADIA Pharmaceuticals (ACAD) as it scales Parkinson's disease therapy and expands into the Rett syndrome segment via the current debt-to-equity ratio.

Analysis of competing companies

Debt to Equity Biogen|Debt to Equity Ratio NBIX (Neurocrine)|Total Debt to Capital RGC|AXSM - Debt to Capital|Xenon Pharmaceuticals - Total Debt to Equity Ratio|Total Debt to Capital vikingtherapeutics.com VKTX|SUPN - Debt to Equity|All Debt to Shareholders' Equity Ratio CPRX (Catalyst Pharma)|Denali Therapeutics Inc (DNLI) - Debt to Equity|Debt to Capital Harmony Corp (HRMY)|BHVN (Biohaven Ltd.) - Total Debt to Capital|Total Debt to Capital amylyx.com|Total Debt to Capital TRVI|Total Debt to Equity Ratio Praxis Precision Medicines Inc PRAX|Total Debt to Capital AVXL (Anavex Corp)|Total Debt to Capital CeriBell EEG CBLL|Prothena Corporation plc - Total Debt to Capital|ALEC (Alector, Inc.) - Debt to Equity Ratio|ANNX: Total Debt to Capital|OMER - Total Debt to Capital Coefficient|NGNE (Neurogene Corp) - Total Debt to Capital|Total Debt to Capital AC Immune Inc|Total Debt to Equity Ratio VYGR (Voyager Therapeutics)|NMRA (neumoratx.com) - All Debt to Shareholders' Equity Ratio|Debt to Equity Scilex SCLX|TVGN (Tevogen Bio Holdings Inc.) - Aggregate Debt to Equity|Alpha Cognition Corp - Total Debt to Capital|All Debt to Shareholders' Equity Ratio CGTX (Cognition Therapeutics Inc.)|IKT: Total Debt to Capital|cassavasciences.com (SAVA) - Total Debt to Capital|Debt to Equity Assertio Holdings|COYA: All Debt to Shareholders' Equity Ratio|Debt to Equity Vistagen Therapeutics (VTGN)|Total Debt to Equity Ratio ovidrx.com OVID|Total Debt to Capital ABOS (Acumen Pharmaceuticals)|Total Debt to Capital cervomed.com CRVO|Alterity Therapeutics Ltd - Total Debt to Capital|Clene Inc. (CLNN) - Total Debt to Equity Ratio|PEPG: Total Debt to Capital|Debt to Capital Jupiter Neurosciences, Inc. (JUNS)|Total Debt to Equity Ratio RLMD|Total Debt to Capital annovisbio.com|Total Debt to Equity Ratio GRCE (Grace Therapeutics, Inc.)|Aggregate Debt to Capital AIFF|Total Debt to Capital KLTO (Klotho Neurosciences)|Total Debt to Capital Coefficient NeuroSense Therapeutics Ltd (NRSN)|Reviva Pharmaceuticals - Total Debt to Capital|MetaVia Inc (MTVA) - Total Debt to Equity Ratio|NRXS: Total Debt to Capital|Helius Medical Technologies (HSDT) - Total Debt to Capital|Debt to Equity Passage Bio Inc.|Debt to Equity NEUP|Debt to Equity Minerva Neurosciences (NERV)|Total Debt to Capital Coefficient athira.com|Total Debt to Capital ADXN (Addex Therapeutics Ltd)|Total Debt to Capital Alzamend Neuro Inc. ALZN|Cyclerion - Total Debt to Capital|Protagenic Therapeutics (PTIX) - Total Debt to Equity Ratio|KTTA: Total Debt to Capital|Cortigent (CRGT) - Total Debt to Capital|ATXI (Avenue Therapeutics, Inc.) - Total Debt to Capital|Debt to Equity Ratio BCLI (Brainstorm Cell Therapeutics Inc.)|Debt to Equity Cara Therapeutics, Inc (CARA)|Chromocell - Debt to Equity Ratio|Total Debt to Capital ELYM (Eliem Therapeutics Inc.)|Intra-Cellular Therapies Inc. (ITCI) - Debt to Capital|LBPH: Total Debt to Equity Ratio|MRNS - Total Debt to Capital|NKGen (NKGN) - Debt to Equity|NeuroBo Pharma - All Debt to Shareholders' Equity Ratio|Debt to Equity Sage Therapeutics, Inc.|Debt to Capital synaptogen.com SNPX|Total Debt to Capital TRVN|Total Debt to Capital vigilneuro.com (VIGL)|Total Debt to Capital WENA (Anew Medical)|CERE - Total Debt to Equity Ratio